Several new approaches to hormonal therapy for men with prostate cancer are showing therapeutic potential, according to studies reported at the American Urological Association (AUA) meeting [San Diego, US; June 1998]. Adjuvant therapy with goserelin significantly improved survival in patients who received radiotherapy for locally advanced prostate cancer. Monotherapy with bicalutamide was therapeutically equivalent to combination therapy with flutamide and goserelin but had a more favourable adverse event profile in patients with advanced prostate cancer. Also, the combination of finasteride and low-dose flutamide may offer effective therapy for biochemical relapse after radiotherapy or radical prostatectomy.